Date of Publication: 11-Feb-2026
INTELLIGENCE OVERVIEW
Agency: US FDA
The FDA has issued a revised Draft Guidance (Revision 2) outlining the updated certification process for Designated Medical Gases (DMGs) under 21 CFR Part 230.
The guidance applies to gases such as oxygen, nitrogen, nitrous oxide, carbon dioxide, helium, and medical air that meet USP-NF compendial standards and are used for specific statutory indications.
Industry Impact:
This update increases regulatory accountability for medical gas manufacturers, strengthens supply chain verification, and enhances market transparency. Companies must ensure compendial compliance, proper facility documentation, and timely reporting to avoid enforcement risk.
The revised framework brings greater clarity to the medical gas approval pathway while raising compliance expectations across the industry.
KEYWORDS: Good Manufacturing Practices (GMP), Pharma Compliance, Helium Therapy
REFERENCE: https://www.fda.gov/media/191040/download https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certification-process-designated-medical-gases